Comparative analysis of mechanical and bioprosthetic valves after aortic valve replacement.
Comparative long-term performance characteristics of Björk-Shiley mechanical and bioprosthetic valves were analyzed for patients undergoing aortic valve replacement between 1976 and 1981. A total of 419 patients received either a standard Björk-Shiley (n = 266) or bioprosthetic (porcine, n = 126, or pericardial, n = 27) aortic valve. Cumulative patient follow-up was 1,705 patient-years; the average patient follow-up was 4.1 +/- 2.7 years. Survival data were obtained for all but 11 patients (97% complete follow-up) up to 9 years after operation. Survival at 5 years was 81% +/- 4% (+/- standard error) for Björk-Shiley and for bioprosthetic valve recipients. Valve failure in the Björk-Shiley group was predominantly due to valve-related mortality and did not result from structural failure. Patients with bioprosthetic valves experienced valve failure as a result of prosthetic valve endocarditis and intrinsic valve degeneration. Although patients with bioprostheses experienced a lower incidence of valve-related morbidity than Björk-Shiley valve recipients (p less than 0.03), no difference could be demonstrated in the incidence of valve-related mortality or valve failure at 5 years between bioprosthetic and Björk-Shiley valves. Mortality rate from valve failure was higher for Björk-Shiley (86%, 12/14) than bioprosthetic valves (36%, 5/14) (p less than 0.01).
D000206:Actuarial Analysis; D000925:Anticoagulants / Q000009:adverse effects; D001021:Aortic Valve; D001705:Bioprosthesis / Q000592:standards*; D004696:Endocarditis / Q000453:epidemiology; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000401:mortality / Q000592:standards*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011183:Postoperative Complications / Q000453:epidemiology; D011474:Prosthesis Design; D012086:Reoperation; D013927:Thrombosis / Q000453:epidemiology; D013997:Time Factors
D000925:Anticoagulants